Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023

J Eur Acad Dermatol Venereol. 2025 Feb;39(2):e153-e154. doi: 10.1111/jdv.20197. Epub 2024 Jun 24.

Authors

Hannah Godfrey¹, Zachary Leibovit-Reiben¹, Patrick Jedlowski², Rebecca Thiede²

Affiliations

¹ University of Arizona College of Medicine-Tucson, Tucson, Arizona, USA.
² Division of Dermatology, University of Arizona College of Medicine-Tucson, Tucson, Arizona, USA.

PMID: 38925559
DOI: 10.1111/jdv.20197

No abstract available

Publication types

Letter